<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id>
<journal-title>Frontiers in Physiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Physiol.</abbrev-journal-title>
<issn pub-type="epub">1664-042X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1089539</article-id>
<article-id pub-id-type="doi">10.3389/fphys.2022.1089539</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Physiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The significant clinical correlation of the intratumor oral microbiome in oral squamous cell carcinoma based on tissue-derived sequencing</article-title>
<alt-title alt-title-type="left-running-head">Li et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphys.2022.1089539">10.3389/fphys.2022.1089539</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhengrui</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1619629/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fu</surname>
<given-names>Rao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2112961/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>Xutao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Qi</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1776570/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Xufeng</given-names>
</name>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1719264/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Ling</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/395569/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Oral and Maxillofacial-Head and Neck Oncology</institution>, <institution>Shanghai Ninth People&#x2019;s Hospital</institution>, <institution>Shanghai Jiao Tong University School of Medicine</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>College of Stomatology</institution>, <institution>Shanghai Jiao Tong University</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>National Center for Stomatology</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>National Clinical Research Center for Oral Diseases</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Shanghai Key Laboratory of Stomatology</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Shanghai Research Institute of Stomatology</institution>, <addr-line>Shanghai</addr-line>, <country>China</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Department of Gastroenterology</institution>, <institution>Affliated Hospital of Jiangsu University</institution>, <institution>Jiangsu University</institution>, <addr-line>Zhenjiang</addr-line>, <country>China</country>
</aff>
<aff id="aff8">
<sup>8</sup>
<institution>Faculty of Dentistry</institution>, <institution>University of Debrecen</institution>, <addr-line>Debrecen</addr-line>, <country>Hungary</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1651221/overview">Simin Li</ext-link>, Southern Medical University, China</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1822990/overview">Xinpei Deng</ext-link>, Sun Yat-sen University Cancer Center (SYSUCC), China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2116407/overview">SiYu Long</ext-link>, Huazhong Agricultural University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1616784/overview">Guy Adami</ext-link>, University of Illinois Chicago, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Ling Zhang, <email>topgun1128@163.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors contributed equally to this work and shared the first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Craniofacial Biology and Dental Research, a section of the journal Frontiers in Physiology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>09</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>1089539</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>12</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Li, Fu, Wen, Wang, Huang and Zhang.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Li, Fu, Wen, Wang, Huang and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>
<bold>Background:</bold> The microbiota is a critical component of the complex human microenvironment, impacting various physiological processes and disease development <italic>via</italic> the microbe&#x2013;host interaction. In particular, the oral microbiota profoundly affects tumor development and progression. There is increasing evidence that oral microbiota is associated with the development of oral cancer, especially oral squamous cell carcinoma (OSCC).</p>
<p>
<bold>Methods:</bold> We comprehensively analyzed the oral microbiota in 133 OSCC samples worldwide. Subsequently, we evaluated the microbial compositions between OSCC patients and healthy people and their correlation with clinical parameters. The value of the oral microbiota as a diagnostic and prognostic biomarker was also determined.</p>
<p>
<bold>Results:</bold> This study found differences in critical oral microbiota between OSCC and normal controls. The most notable differences are present in <italic>p_Firmicutes</italic>, <italic>p_Actinobacteria</italic>, <italic>c_Fusobacteriia</italic>, <italic>o_Fusobacteriales</italic>, <italic>f_Fusobacteriaceae</italic>, and <italic>g_Fusobacterium</italic>. All six-level oral microorganisms were also associated with the clinical characteristics of OSCC, particularly with the clinical outcomes (survival time and status). We developed a predictive model based on this. We found that five different oral microorganisms have high confidence and can be used for clinical diagnosis and prognostic prediction, except for <italic>p_Actinobacteria</italic>.</p>
<p>
<bold>Conclusion:</bold> This study revealed that the intratumor oral microbiota of OSCC patients worldwide and the microbial signatures of OSCC patients possess similar properties in different regions, further refining the shortcomings of the current research field. We revealed that the oral microbiota could be used as a biomarker to reflect human health and disease progression status. This will provide new directions for tumor microbiome research. This means we can develop strategies through diet, probiotics, and antibiotics for cancer prevention and treatment.</p>
</abstract>
<kwd-group>
<kwd>oral squamous cell carcinoma</kwd>
<kwd>oral microbiota</kwd>
<kwd>intratumor microbiota</kwd>
<kwd>biomarker</kwd>
<kwd>sequencing</kwd>
<kwd>
<italic>Fusobacterium</italic>
</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The microbiota is one of the critical components of the human body and constitutes a range of complex microenvironments (<xref ref-type="bibr" rid="B6">Chen et al., 2022</xref>). The microbiota affects various physiological processes and diseases (especially tumors) in the body <italic>via</italic> the microbe&#x2013;host interaction. With the progression of human microbiome research, we have increasingly focused on microbial enrichment sites (such as the oral (<xref ref-type="bibr" rid="B2">Almangush et al., 2020</xref>) 31 cavity, airway, gastrointestinal tract, skin, and urinary tract) (<xref ref-type="bibr" rid="B19">Rubin et al., 2022</xref>). Research suggests that disease occurrence is closely related to the site&#x2019;s microbiota (<xref ref-type="bibr" rid="B30">Young, 2017</xref>; <xref ref-type="bibr" rid="B16">Manor et al., 2020</xref>), especially gut microbiota and digestive tract diseases (<xref ref-type="bibr" rid="B15">Lynch and Pedersen, 2016</xref>). Oral diseases and oral microbiota are also not excepted (<xref ref-type="bibr" rid="B21">Sedghi et al., 2021</xref>).</p>
<p>Until not long ago, most oral microbiota studies have focused on non-tumor diseases (<xref ref-type="bibr" rid="B22">Solbiati and Frias-Lopez, 2018</xref>), such as periodontitis, gingivitis, and caries. However, studies on oral cancer (OC) have also gradually attracted attention, especially with the most popular type&#x2014;oral squamous cell carcinoma (OSCC). We found that multiple OC risk factors, including alcohol consumption, smoking, and betel nut chewing, can change the community structure of oral microbiota. Coincidentally, the abundance of oral microbiota has also changed considerably in oral precancerous lesions (leukoplakia and lichen planus) (<xref ref-type="bibr" rid="B13">Li et al., 2021</xref>). Also, the microbial composition of paired tumor (TT)/normal paracancerous tissues (NPT) and saliva (TS) samples in OSCC patients shows significant differences (<xref ref-type="bibr" rid="B29">Yang, Wang et al., 2021</xref>). A study on OSCC patients of the Indian subcontinent has indicated the possibility of using the microbiome as a prognostic marker in patients with oral malignancies (<xref ref-type="bibr" rid="B20">Sarkar, Malik et al., 2021</xref>). These findings suggest an inextricable potential link between oral microbiota and OSCC.</p>
<p>Our previous study showed significant changes in oral microbiota on the surface of OSCC tissues (<xref ref-type="bibr" rid="B31">Zhang et al., 2019</xref>), compared with the surface of healthy tissues. In addition, various oral pathogenic microorganisms have been shown to activate and promote the growth of OSCC (<xref ref-type="bibr" rid="B12">Irfan et al., 2020</xref>). We consistently found that the abundance of certain microorganisms such as <italic>Prevotella intermedia</italic> (<italic>P. intermedia</italic>) and <italic>Fusobacterium nucleatum (F. nucleatum)</italic> increased significantly as tumor progressed through metagenomic analysis (<xref ref-type="bibr" rid="B14">Liu et al., 2022</xref>). This demonstrates that the high abundance of certain oral microorganisms is closely related to the progression of the disease or the advanced stage of OSCC. Most studies on the microbiota of OSCC have been limited to oral swabs (tumor surface) or saliva (intrasalivary gland). However, in one study, deep swabbing was performed to recover bacteria within tissue rather than surface bacteria (<xref ref-type="bibr" rid="B1">Al-Hebshi et al., 2017</xref>). Also, in another study, deep tumor tissue samples&#x2014;oral fibroepithelial polyp (FEP) tissues&#x2014;were analyzed (<xref ref-type="bibr" rid="B18">Perera et al., 2018</xref>). These remind us that systematic analysis of intratumor oral microbiota is required as comprehensively as possible. However, there have been some studies on intracellular bacteria, like <italic>P. gingivalis</italic>. Furthermore, the oral microbiota&#x2019;s potential clinical importance in OSCC patients remains uncertain, especially the correlation with clinical, pathological, and molecular characteristics.</p>
<p>The tumor surface oral microbiota in the oral microenvironment influences intratumor microbial changes. OSCC further produces a series of microbe&#x2013;host interactions with oral microbiota, resulting in the entry of microorganisms into the tumor, which causes multiple functional changes. In our study, we hypothesized that some pathogenic microorganisms might be associated with the development and clinical characteristics of OSCC. We used The Cancer Microbiome Atlas (TCMA) to test our hypothesis (<xref ref-type="bibr" rid="B8">Dohlman et al., 2021</xref>). It is a complex microbiome aggregation based on whole-exome sequencing (WES) and whole-genome sequencing (WGS) data and contains collated and purified microbiota profiles of 3,689 oral, oropharyngeal, esophageal, intestinal, and colorectal tissues from 1,772 patients; it is a valuable tool for the further exploration of microbial function within designated tumor tissues. We screened 132 standard OSCC cases (including 112 OSCC primary tumor samples/20 solid tissue normal samples), examined the abundance of oral microorganisms in tumor in all cases, and then looked for their clinical information through a comprehensive database. Combined with multiomics data, the relationship between the abundance of intratumor oral microorganisms and OSCC was explored. The value of the oral intratumor microbiota as a potential marker for tumor diagnosis and prognosis was determined, and the characteristics and composition differences of the intratumor microbiota in OSCC were revealed (<xref ref-type="fig" rid="F1">Figure 1</xref>). It offers a theoretical and experimental basis for further research about the mechanism of the oral microbiota in oral cancer and new ideas and methods for clinical diagnosis and treatment.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Existence and manifestation of the oral microbiota in OSCC. Intratumor oral microbiota of tumor/normal tissue was obtained through an oral swab. Microbial abundance was determined by high-throughput sequencing, and early diagnosis and prognosis prediction of OSCC were performed.</p>
</caption>
<graphic xlink:href="fphys-13-1089539-g001.tif"/>
</fig>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Data collection and preprocessing</title>
<p>In our study, we collected microbiota profiling data at phylum, class, order, family, and genus levels from 132 samples of TCMA (including 112 OSCC primary tumor samples and 20 solid tissue normal samples). The relevant patients&#x2019; clinical information (classification was performed using NCCN Guidelines &#x2018;Head and Neck Cancers&#x2019; Version 2.2022 (<xref ref-type="bibr" rid="B4">Caudell et al., 2022</xref>)) is shown (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>General characteristics of OSCC patients.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Characteristic</th>
<th align="left">
</th>
<th align="left">OSCC</th>
<th align="left">Normal</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Age, (mean &#xb1; SD)</td>
<td align="left">
</td>
<td align="left">60.52 &#xb1; 13.14</td>
<td align="left">58.31 &#xb1; 12.72</td>
</tr>
<tr>
<td rowspan="2" align="left">Gender, n (%)</td>
<td align="left">Female</td>
<td align="left">36 (32.1%)</td>
<td align="left">7 (35%)</td>
</tr>
<tr>
<td align="left">Male</td>
<td align="left">76 (67.9%)</td>
<td align="left">13 (65%)</td>
</tr>
<tr>
<td rowspan="2" align="left">Alcohol, n (%)</td>
<td align="left">No</td>
<td align="left">36 (32.1%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Yes</td>
<td align="left">76 (67.9%)</td>
<td align="left"/>
</tr>
<tr>
<td rowspan="2" align="left">Smoking, n (%)</td>
<td align="left">No</td>
<td align="left">3 (2.7%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Yes</td>
<td align="left">109 (97.3%)</td>
<td align="left"/>
</tr>
<tr>
<td rowspan="5" align="left">Anatomic site, n (%)</td>
<td align="left">Alveolar ridge</td>
<td align="left">6 (5.4%)</td>
<td align="left">(0%)</td>
</tr>
<tr>
<td align="left">Buccal mucosa</td>
<td align="left">4 (3.6%)</td>
<td align="left">(0%)</td>
</tr>
<tr>
<td align="left">Floor of the mouth</td>
<td align="left">11 (9.8%)</td>
<td align="left">(0%)</td>
</tr>
<tr>
<td align="left">Hard palate</td>
<td align="left">3 (2.7%)</td>
<td align="left">1 (5%)</td>
</tr>
<tr>
<td align="left">Oral cavity</td>
<td align="left">25 (22.3%)</td>
<td align="left">4 (20%)</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Tongue</td>
<td align="left">63 (56.2%)</td>
<td align="left">15 (75%)</td>
</tr>
<tr>
<td rowspan="5" align="left">T stage (tumor), n (%)</td>
<td align="left">TX</td>
<td align="left">9 (8%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">T1</td>
<td align="left">11 (9.8%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">T2</td>
<td align="left">31 (27.7%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">T3</td>
<td align="left">21 (18.8%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">T4</td>
<td align="left">39 (34.8%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Not available</td>
<td align="left">1 (.9%)</td>
<td align="left"/>
</tr>
<tr>
<td rowspan="5" align="left">N stage (node), n (%)</td>
<td align="left">Nx</td>
<td align="left">19 (17%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">N0</td>
<td align="left">40 (35.7%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">N1</td>
<td align="left">14 (12.5%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">N2</td>
<td align="left">36 (32.1%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">N3</td>
<td align="left">1 (.9%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Not available</td>
<td align="left">2 (1.8%)</td>
<td align="left"/>
</tr>
<tr>
<td rowspan="2" align="left">M stage (metastasis), n (%)</td>
<td align="left">M0</td>
<td align="left">16 (14.3%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Not available</td>
<td align="left">96 (85.7%)</td>
<td align="left"/>
</tr>
<tr>
<td rowspan="4" align="left">Pathologic stage, n (%)</td>
<td align="left">Stage I</td>
<td align="left">7 (6.2%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Stage II</td>
<td align="left">22 (19.6%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Stage III</td>
<td align="left">16 (14.3%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Stage IVA/B</td>
<td align="left">55 (49.1%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Not available</td>
<td align="left">12 (10.7%)</td>
<td align="left"/>
</tr>
<tr>
<td rowspan="4" align="left">Histologic grade, n (%)</td>
<td align="left">GX</td>
<td align="left">3 (2.7%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">G1</td>
<td align="left">11 (9.8%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">G2</td>
<td align="left">69 (61.6%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">G3</td>
<td align="left">28 (25%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left"/>
<td align="left">G4</td>
<td align="left">1 (.9%)</td>
<td align="left"/>
</tr>
<tr>
<td colspan="4" align="left">Overall survival</td>
</tr>
<tr>
<td align="left">OS time (day), (mean &#xb1; SD)</td>
<td align="left">
</td>
<td align="left">1,026.26 &#xb1; 861.92</td>
<td align="left"/>
</tr>
<tr>
<td align="left">OS status, n (%)</td>
<td align="left">Alive</td>
<td align="left">56 (50%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Dead</td>
<td align="left">56 (50%)</td>
<td align="left"/>
</tr>
<tr>
<td colspan="4" align="left">Disease-free survival</td>
</tr>
<tr>
<td align="left">DFS time (day), mean &#xb1; SD.</td>
<td align="left">
</td>
<td align="left">1,072.58 &#xb1; 945.13</td>
<td align="left"/>
</tr>
<tr>
<td align="left">DFS status, n (%)</td>
<td align="left">Alive</td>
<td align="left">73 (65.2%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left"/>
<td align="left">Dead</td>
<td align="left">39 (34.8%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">Total number</td>
<td align="left"/>
<td align="left">112</td>
<td align="left">20</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-2">
<title>Intratumor oral microbiota profile analysis of OSCC</title>
<p>We calculated each sample&#x2019;s relative abundance and composition of oral microorganisms about the phylum, class, order, family, and genus levels. We identified organisms with an average abundance of &#x3e;1% for further investigation. The overall microbial signatures of OSCC/normal groups were investigated after discriminant analysis. The partial least squares-discriminant analysis (PLS-DA) model assessed the differences of tumor samples under different conditions, such as age, gender, anatomical sites, and tumor stage.</p>
</sec>
<sec id="s2-3">
<title>Statistical and bioinformatics analysis</title>
<p>R (version 4.0.2) and GraphPad Prism 9.0 software applications were used for statistical data analysis. The t-test was used to compare the groups to identify microbial differences between OSCC and normal samples (<italic>p</italic> &#x3c; .05 indicating statistical significance). We used the R language &#x201c;ggtree&#x201d; package for LEfSe analysis. The &#x201c;ROC&#x201d; package of R was used for ROC curve analysis of differential oral microorganisms, and the area under the curve (AUC) represented their predictive ability (<italic>p</italic> &#x3c;.05 were considered statistically significant). Survival curves for each oral microorganism of OSCC patients were estimated using Kaplan&#x2013;Meier curves and compared by the log-rank test.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Differential oral microbiota profile in OSCC and normal tissues</title>
<p>A total of 11 phyla, 22 classes, 38 orders, 67 families, and 221 genera of oral microbial taxa were extracted in all OSCC and normal tissue samples, and microorganisms with insufficient relative abundance were filtered out after calculation and screening. Finally, six phyla, 23 classes, 13 orders, 17 families, and 16 genera of oral microorganisms have a relative abundance greater than 1%. It is of practical significance and can be used for subsequent data statistics and analyses. We presented the top organisms in the total abundance in the oral microbiota at different levels and the structural differences between the two groups (OSCC and healthy controls), as well as the relative proportions in the respective levels by percentage stacking histograms.</p>
<p>At the phylum level, the relative abundances of <italic>p_Fusobacteria</italic> and <italic>p_Spirochaetes</italic> increased in OSCC tumor tissues, while the relative abundances of <italic>p_Firmicutes</italic> and <italic>p_Actinobacteria</italic> decreased (<xref ref-type="fig" rid="F2">Figure 2A</xref>). At the class level, the relative abundances of <italic>c_Fusobacteriia</italic>, <italic>c_Spirochaetia</italic>, and <italic>c_Flavobacteriia</italic> increased in OSCC tumor tissues, while the relative abundances of <italic>c_Bacterioidia</italic>, <italic>c_Bacilli</italic>, <italic>c_Actinobacteria</italic>, <italic>c_Negativicutes</italic>, and <italic>c_Coribacteriia</italic> decreased (<xref ref-type="fig" rid="F2">Figure 2B</xref>). At the order level, <italic>o_Fusobacteriales</italic>, <italic>o_Spirochaetales</italic>, and <italic>o_Flavobacteriales</italic> showed significantly higher expression in tumor tissues, while <italic>o_Micrococcales</italic> showed lower expression (<xref ref-type="fig" rid="F2">Figure 2C</xref>). Regarding family and genera, <italic>f_Fusobacteriaceae</italic>, <italic>f_Spirochaetaceae</italic>, <italic>f_Flavobacteriia</italic>, <italic>g_Fusobacterium</italic>, <italic>g_Treponema</italic>, and <italic>g_Capnocytophaga</italic> showed significantly high abundances, while most of the remaining microbiota showed low abundances (<xref ref-type="fig" rid="F2">Figure 2D, E</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Oral microbiota profile analyses of OSCC tumor and normal tissue based on five different microbial levels. <bold>(A&#x2013;E)</bold>. Oral microbial composition with &#x3e;1% difference in relative abundances between OSCC and normal controls (statistically significant between group comparisons, <italic>p</italic> &#x3c; .05).</p>
</caption>
<graphic xlink:href="fphys-13-1089539-g002.tif"/>
</fig>
<p>To further validate the different levels of microorganisms, we selected those oral microorganisms (with &#x3e;1% difference in relative abundances) and further identified differences between the two groups using LEfSe discriminant analyses (with an LDA value of 2). To our surprise, analyses of the five levels showed significant abundance differences in <italic>o_Fusobacteriales</italic>, <italic>g_Fusobacterium</italic>, <italic>c_Fusobacteriia</italic>, <italic>p_Fusobacteria</italic>, and <italic>f_Fusobacteriaceae</italic> in OSCC (<xref ref-type="fig" rid="F3">Figure 3A</xref>), which is consistent with our previous stacking histogram results.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>LEfSe analyses identifying OSCC and normal tissue-enriched oral microorganisms. <bold>(A)</bold>. LDA score of specific microbial taxa in the OSCC and normal groups (the threshold LDA score is 2) <bold>(B&#x2013;F)</bold>. PCA plots of OSCC and normal tissue samples based on oral microbiota analyses at phylum, class, order, family, and genus levels (one plot characterizes one sample, and the large ellipses in each group represent the 95% confidence interval (CI) range of the matching group. Paired samples were selected for this group).</p>
</caption>
<graphic xlink:href="fphys-13-1089539-g003.tif"/>
</fig>
<p>We also performed principal component analyses (PCA) of oral microorganisms in these five levels of OSCC tissues and normal tissues. Abundances were ranked based on Bray&#x2013;Curtis distance and overall compositional structural differences between groups from phylum to genus; OSCC samples and healthy tissues were identified by PCA (<xref ref-type="fig" rid="F2">Figures 2B&#x2013;F</xref>), further confirming structural differences in microbiota between the two groups.</p>
</sec>
<sec id="s3-2">
<title>Diagnostic value of oral microbiota in OSCC</title>
<p>We have previously demonstrated significant differences in the intratumor oral microbiota and then verified the predictive capacity of these microorganisms for OSCC, especially several key intratumor oral microorganisms with higher abundances (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;E</xref>). The statistical analyses finally showed that most oral microorganisms with higher abundances in normal tissues could not be used as tumor biomarkers for OSCC, which is unable to distinguish OSCC tumors from normal tissues. However, some typical pathogenic oral microorganisms, such as <italic>p_Firmicutes</italic> (AUC &#x3d; .705), <italic>p_Actinobacteria</italic> (AUC &#x3d; .772), <italic>c_Fusobacteriia</italic> (AUC &#x3d; .686), <italic>o_Fusobacteriales</italic> (AUC &#x3d; .694), <italic>f_Fusobacteriaceae</italic> (AUC &#x3d; .688), and <italic>g_Fusobacterium</italic> (AUC &#x3d; .689), have strong predictive ability in distinguishing OSCC (<xref ref-type="fig" rid="F4">Figures 4F&#x2013;J</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Differential oral microbiota composition and ROC analyses at different levels in OSCC tumors and normal tissues <bold>(A&#x2013;E)</bold> <bold>(F&#x2013;J)</bold>.</p>
</caption>
<graphic xlink:href="fphys-13-1089539-g004.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>Association of oral microbiota with clinical characteristics of OSCC</title>
<p>We further investigated all six levels of oral microorganisms with strong diagnostic values to predict their association with OSCC clinical features.</p>
<p>We examined the distribution of these six key oral microorganisms, and PCA showed that their expressions were more significant in tumor tissues than in control tissues (<xref ref-type="fig" rid="F5">Figure 5A, B</xref>). Further examining the distribution of these six levels of oral microorganisms in OSCC tumor tissues, we found that <italic>g_Fusobacterium</italic> was the most widely distributed and abundant.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Distribution of six different levels of oral microorganisms in OSCC. <bold>(A)</bold>. Principal component analysis (PCA) plots showed six levels of oral microbial distribution profile (OSCC/normal controls). OSCC patients presented with a higher abundance of key microbial biomarkers than healthy controls. <bold>(B)</bold>. Circle histogram showed the distribution of oral microorganisms after normalization, g_<italic>Fusobacterium</italic> was present in almost all OSCC patients, and the abundance gradually increased.</p>
</caption>
<graphic xlink:href="fphys-13-1089539-g005.tif"/>
</fig>
<p>Based on different clinical parameter characteristics of OSCC patients, we investigated the clinical relevance of crucial oral microorganisms. All OSCC tumor samples were divided equally into subgroups according to sex, age, tumor stage, histological grade, and anatomical site of the lesion. We found that different levels of key oral microorganisms tend to differ between subgroups (<xref ref-type="fig" rid="F6">Figure 6</xref>). These findings may suggest some correlation between clinical parameter characteristics and crucial oral microorganisms in OSCC patients.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Oral microbiota analyses of OSCC tumors based on different clinical parameter subgroups <bold>(A&#x2013;E)</bold>.</p>
</caption>
<graphic xlink:href="fphys-13-1089539-g006.tif"/>
</fig>
<p>The PLS-DA plot between six different levels of microorganisms in the subgroup of OSCC based on sex (A), age (B), tumor stage (C), histological grade (D), and the anatomical site of lesion (E) (dot: sample, ellipse: 95% CI of the subgroup sample).</p>
<p>We then used KM survival analyses to select the optimal cutoff value, according to the abundances of oral microorganisms and divided OSCC patients into high/low abundance subgroups. The survival curves were fitted and visualized. We finally detected several key oral microorganisms. The other five levels of oral microorganisms showed great diagnostic efficacy in OSCC patients&#x2019; prediction and prognosis (<xref ref-type="fig" rid="F7">Figures 7A&#x2013;F</xref>), except <italic>p_Actinobacteria</italic>.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>KM survival curves for key oral microorganisms in OSCC patients. A low abundance of <italic>p_Firmicutes</italic> <bold>(A)</bold> and high abundances of <italic>c_Fusobacteriia</italic> <bold>(C)</bold>, <italic>o_Fusobacteriales</italic> <bold>(D)</bold>, <italic>f_Fusobacteriaceae</italic> <bold>(E)</bold>, and <italic>g_Fusobacterium </italic>
<bold>(F)</bold> represented poor clinical outcomes (<italic>p</italic> &#x3c; .05). However, there was no significant relationship between p_Actinobacteria <bold>(B)</bold> and the outcome of patients (<italic>p</italic> &#x3d; .535) (grouping is best truncated based on specific microbial abundance and divided into high and low groups).</p>
</caption>
<graphic xlink:href="fphys-13-1089539-g007.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>OSCC is one of the most common malignant tumors of the head and neck (<xref ref-type="bibr" rid="B26">Warnakulasuriya and Kerr, 2021</xref>), accounting for more than 90% of malignant epithelial tumors. Studies show that high incidence and mortality in OSCC are higher in mainland Asia than in other regions (<xref ref-type="bibr" rid="B5">Chai et al., 2020</xref>). The current diagnosis of OSCC is based on biopsy, and most patients are clinically diagnosed during advanced stages (<xref ref-type="bibr" rid="B2">Almangush et al., 2020</xref>). Furthermore, OSCC also shows powerful potential for regional and distant metastasis (<xref ref-type="bibr" rid="B3">Bugshan and Farooq, 2020</xref>), which causes a high recurrence rate and an unfortunate prognosis for OSCC with 5-year overall survival of only 40%&#x2013;50% (<xref ref-type="bibr" rid="B17">Nagao and Warnakulasuriya, 2020</xref>). However, the overall survival of OSCC patients diagnosed with early-stage tumors can rise significantly to more than 85% (<xref ref-type="bibr" rid="B10">Huang et al., 2019</xref>). Therefore, accurate and timely early diagnosis is essential to improve the prognosis and life quality of OSCC patients. Thus, searching for key feasible diagnostic and prognostic biomarkers will provide new directions and theoretical basis for the future early warning and biological diagnosis and treatment of OSCC.</p>
<p>Previous studies have found that intratumor microorganisms, particularly intratumor bacteria, are characterized by different compositions in multiple cancer types. Our study united multiomics data from corresponding and global OSCC tissue samples for in-depth analyses. The differences in intratumor oral microbiota between OSCC and normal tissues were revealed at five levels (phylum, class, order, family, and genus). Potential links of key oral microorganisms as tumor biomarkers for OSCC to guide diagnosis and prognosis were explored. We focused on oral microorganisms with the potential diagnostic and prognostic value at different levels in OSCC.</p>
<p>Oral microbiota is a highly abundant and diverse microbial population, whose interactions with the host influence various physiological processes (<xref ref-type="bibr" rid="B7">Cullin et al., 2021</xref>). Certain individual members of the oral microbiota have various pathophysiological functions that promote cancer initiation, progression, and invasion (<xref ref-type="bibr" rid="B12">Irfan et al., 2020</xref>). Alterations in the structure and composition of the oral microbiota cannot be ignored during the evolution from a normal state to cancer. Oral microorganisms in OSCC differ in abundances at all levels compared to healthy tissues. In particular, <italic>Fusobacterium</italic> showed high abundance at all five levels. In general, our results agree well with the previous study, which similarly observed enrichment for <italic>p_Fusobacteriia</italic>, <italic>o_Fusobacteriales</italic>, and <italic>g_Fusobacterium</italic> (<xref ref-type="bibr" rid="B25">Wang et al., 2022</xref>). Further studies revealed that six microorganisms, <italic>p_Firmicutes</italic>, <italic>p_Actinobacteria</italic>, <italic>c_Fusobacteriia</italic>, <italic>o_Fusobacteriales</italic>, <italic>f_Fusobacteriaceae</italic>, and <italic>g_Fusobacterium</italic>, had solid predictive ability in distinguishing OSCC. Except <italic>p_Actinobacteria</italic>, the other five oral microorganisms showed great efficacy in predicting the prognosis of OSCC patients. This suggests the value of various levels of critical oral microorganisms as potential biomarkers for the diagnosis and prognosis of OSCC. In addition, we found some correlation between clinical characteristics of OSCC and oral microbiome, which awaits further clinical studies in the future.</p>
<p>As mentioned previously, we observed an increase in the abundance of <italic>g_Fusobacterium</italic> and a decrease in <italic>p_Firmicutes</italic> and <italic>p_Actinobacteria</italic> in OSCC. <italic>g_Fusobacterium</italic> is a Gram-negative anaerobic bacterium that belongs to the normal group of oral microbiota and is usually present in oral cavities and mucosal sites. At the same time, it is also an invasive oral pathogen in pathophysiology (<xref ref-type="bibr" rid="B24">Sun et al., 2019</xref>) and a significant contributor to the increased expression of virulence factors in the oral microbiota (<xref ref-type="bibr" rid="B31">Zhang et al., 2019</xref>). Several studies have shown that the abundance of g_<italic>Fusobacterium</italic> is significantly higher in OSCC tumor tissues than in normal tissues (<xref ref-type="bibr" rid="B28">Yang et al., 2018</xref>). This is consistent with our findings (<xref ref-type="bibr" rid="B14">Liu et al., 2022</xref>). g_<italic>Fusobacterium</italic> can enhance cancer invasiveness, survival, and epithelial&#x2013;mesenchymal transfer (EMT) of cancer in the oral tumor microenvironment (<xref ref-type="bibr" rid="B23">Stasiewicz and Karpinski, 2021</xref>). It promotes the development and progression of OSCC by binding to TLR2 receptors expressed on the surface of OSCC cells, stimulating the production of IL6 and the activation of STAT3, inducing downstream effector molecules, which in turn, stimulates cell proliferation, migration, and invasion, and causes inflammation (<xref ref-type="bibr" rid="B9">Hsiao et al., 2018</xref>). Interestingly, the changes in the abundance of five predictive microbial markers contribute to the inflammatory state of the oral epithelium. This may provide some ideas for oral microorganisms to promote inflammation cancer transformation of the oral epithelium.</p>
<p>The strength of this study is that the OSCC samples in our data come from different hospitals around the world, increasing the generalizability of our findings. Importantly, we comprehensively described and analyzed the differences in intratumor oral microbiota between OSCC and healthy tissues from five different microbial levels and further revealed their potential value in diagnosis and prognosis. Our findings provide evidence of changes in oral microbes during OSCC progression and raise the possibility that different levels of key oral microbes may serve as potential biomarkers for OSCC diagnosis and prognosis, especially g_<italic>Fusobacterium</italic>. This provides a new perspective for tumor microbiome research and valuable insights into the clinical diagnosis and treatment of OSCC. However, these findings must be validated in other populations, and clinical validation is crucial to clinical applications of tumor tissue biomarkers. Once successful, it will herald the possibility of g_<italic>Fusobacterium</italic> DNA as a prognostic biomarker in OSCC. This is similar to identifying markers of cell death to predict the clinical treatment of tumors (<xref ref-type="bibr" rid="B32">Zou et al., 2019</xref>), such as breast cancer (<xref ref-type="bibr" rid="B10">Huang et al., 2019</xref>; <xref ref-type="bibr" rid="B27">Xie et al., 2019</xref>). In addition, our population-based statistics may provide insights to develop strategies to prevent and treat oral cancer by targeting the oral microbiota for future studies.</p>
<p>Overall, this study offers a further understanding of the oral microbial composition of OSCC patients. However, systematic studies are needed to detect the exact mechanism of oral microorganisms in OSCC if they are to be transferred into clinical use.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>This study revealed that the intratumor oral microbiota of OSCC patients worldwide and the microbial signatures of OSCC patients possess similar properties in different regions. We revealed that the oral microbiota could be used as a biomarker to reflect human health and disease progression status. This will provide new directions for tumor microbiome research. This means we can develop cancer prevention and treatment strategies through diet, probiotics, and antibiotics (<xref ref-type="bibr" rid="B11">Huang et al., 2022</xref>).</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s6">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="s11">Supplementary Material</xref>.</p>
</sec>
<sec id="s7">
<title>Author contributions</title>
<p>Research concepts and design: LZ. Data acquisition: ZL, RF, and XW. Data analysis and interpretation: RF, XW, QW, and XH. Manuscript drafting: ZL, QW, and XH. Key revision and final approval of the manuscript: LZ. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>The work was supported by the National Natural Science Foundation of China (81771127), the Natural Science Foundation of Xinjiang Uygur Autonomous Region (2022D01C15), the Medical Engineering Cross Foundation of Shanghai Jiao Tong University (YG2015MS06), and the Seed Fund of the Ninth People&#x2019;s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (JYZZ196).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphys.2022.1089539/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphys.2022.1089539/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.ZIP" id="SM1" mimetype="application/ZIP" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="DataSheet2.ZIP" id="SM2" mimetype="application/ZIP" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Hebshi</surname>
<given-names>N. N.</given-names>
</name>
<name>
<surname>Nasher</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Maryoud</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Homeida</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Idris</surname>
<given-names>A. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Inflammatory bacteriome featuring Fusobacterium nucleatum and <italic>Pseudomonas aeruginosa</italic> identified in association with oral squamous cell carcinoma</article-title>. <source>Sci. Rep.</source> <volume>7</volume> (<issue>1</issue>), <fpage>1834</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-02079-3</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almangush</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Makitie</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Triantafyllou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>de Bree</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Strojan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rinaldo</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Staging and grading of oral squamous cell carcinoma: An update</article-title>. <source>Oral Oncol.</source> <volume>107</volume>, <fpage>104799</fpage>. <pub-id pub-id-type="doi">10.1016/j.oraloncology.2020.104799</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bugshan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Farooq</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Oral squamous cell carcinoma: Metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis</article-title>. <source>F1000Res.</source> <volume>9</volume>, <fpage>229</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.22941.1</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caudell</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Gillison</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Maghami</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pfister</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>NCCN Guidelines&#xae; insights: Head and neck cancers, version 1.2022</article-title>. <source>J. Natl. Compr. Canc Netw.</source> <volume>20</volume> (<issue>3</issue>), <fpage>224</fpage>&#x2013;<lpage>234</lpage>. <pub-id pub-id-type="doi">10.6004/jnccn.2022.0016</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname>
<given-names>A. W. Y.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Cheong</surname>
<given-names>S. C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Translational genomics and recent advances in oral squamous cell carcinoma</article-title>. <source>Semin. Cancer Biol.</source> <volume>61</volume>, <fpage>71</fpage>&#x2013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2019.09.011</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F. H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P. Q.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The role of the tumor microbiome in tumor development and its treatment</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>935846</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.935846</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cullin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Azevedo Antunes</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Straussman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Stein-Thoeringer</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Elinav</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Microbiome and cancer</article-title>. <source>Cancer Cell</source> <volume>39</volume> (<issue>10</issue>), <fpage>1317</fpage>&#x2013;<lpage>1341</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2021.08.006</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dohlman</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Arguijo Mendoza</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dressman</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Iliev</surname>
<given-names>I. D.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The cancer microbiome atlas: A pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants</article-title>. <source>Cell Host Microbe</source> <volume>29</volume> (<issue>2</issue>), <fpage>281</fpage>&#x2013;<lpage>298.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2020.12.001</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsiao</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>S. T.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>The interplay between oral microbiome, lifestyle factors and genetic polymorphisms in the risk of oral squamous cell carcinoma</article-title>. <source>Carcinogenesis</source> <volume>39</volume> (<issue>6</issue>), <fpage>778</fpage>&#x2013;<lpage>787</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgy053</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>G. Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q. Q.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z. N.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>X. Z.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Identification of candidate biomarkers and analysis of prognostic values in oral squamous cell carcinoma</article-title>. <source>Front. Oncol.</source> <volume>9</volume>, <fpage>1054</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2019.01054</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Circular RNA KIF4A promotes liver metastasis of breast cancer by reprogramming glucose metabolism</article-title>. <source>J. Oncol.</source> <volume>2022</volume>, <fpage>8035083</fpage>. <pub-id pub-id-type="doi">10.1155/2022/8035083</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irfan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delgado</surname>
<given-names>R. Z. R.</given-names>
</name>
<name>
<surname>Frias-Lopez</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The oral microbiome and cancer</article-title>. <source>Front. Immunol.</source> <volume>11</volume>, <fpage>591088</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.591088</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Characterization of the oral and esophageal microbiota in esophageal precancerous lesions and squamous cell carcinoma</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>11</volume>, <fpage>714162</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2021.714162</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Metagenomic analysis reveals a changing microbiome associated with the depth of invasion of oral squamous cell carcinoma</article-title>. <source>Front. Microbiol.</source> <volume>13</volume>, <fpage>795777</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2022.795777</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>The human intestinal microbiome in health and disease</article-title>. <source>N. Engl. J. Med.</source> <volume>375</volume> (<issue>24</issue>), <fpage>2369</fpage>&#x2013;<lpage>2379</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1600266</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manor</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Kornilov</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>Lovejoy</surname>
<given-names>J. C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Health and disease markers correlate with gut microbiome composition across thousands of people</article-title>. <source>Nat. Commun.</source> <volume>11</volume> (<issue>1</issue>), <fpage>5206</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-18871-1</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Warnakulasuriya</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Screening for oral cancer: Future prospects, research and policy development for Asia</article-title>. <source>Oral Oncol.</source> <volume>105</volume>, <fpage>104632</fpage>. <pub-id pub-id-type="doi">10.1016/j.oraloncology.2020.104632</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perera</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Al-hebshi</surname>
<given-names>N. N.</given-names>
</name>
<name>
<surname>Perera</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ipe</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ulett</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Speicher</surname>
<given-names>D. J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Inflammatory bacteriome and oral squamous cell carcinoma</article-title>. <source>J. Dent. Res.</source> <volume>97</volume> (<issue>6</issue>), <fpage>725</fpage>&#x2013;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1177/0022034518767118</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubin</surname>
<given-names>B. E.</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cress</surname>
<given-names>B. F.</given-names>
</name>
<name>
<surname>Crits-Christoph</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Borges</surname>
<given-names>A. L.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Species- and site-specific genome editing in complex bacterial communities</article-title>. <source>Nat. Microbiol.</source> <volume>7</volume> (<issue>1</issue>), <fpage>34</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1038/s41564-021-01014-7</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Malik</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Laha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bunk</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ray</surname>
<given-names>J. G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Dysbiosis of oral microbiota during oral squamous cell carcinoma development</article-title>. <source>Front. Oncol.</source> <volume>11</volume>, <fpage>614448</fpage>. <pub-id pub-id-type="doi">10.3389/fonc.2021.614448</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sedghi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>DiMassa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Harrington</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Kapila</surname>
<given-names>Y. L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The oral microbiome: Role of key organisms and complex networks in oral health and disease</article-title>. <source>Periodontol</source> <volume>87</volume> (<issue>1</issue>), <fpage>107</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1111/prd.12393</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solbiati</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Frias-Lopez</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Metatranscriptome of the oral microbiome in health and disease</article-title>. <source>J. Dent. Res.</source> <volume>97</volume> (<issue>5</issue>), <fpage>492</fpage>&#x2013;<lpage>500</lpage>. <pub-id pub-id-type="doi">10.1177/0022034518761644</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stasiewicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Karpinski</surname>
<given-names>T. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The oral microbiota and its role in carcinogenesis</article-title>. <source>Semin. Cancer Biol.</source> <volume>86</volume>, <fpage>633</fpage>&#x2013;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcancer.2021.11.002</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B. B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T. T.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>The role of Fusobacterium nucleatum in colorectal cancer: From carcinogenesis to clinical management</article-title>. <source>Chronic Dis. Transl. Med.</source> <volume>5</volume> (<issue>3</issue>), <fpage>178</fpage>&#x2013;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/j.cdtm.2019.09.001</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>A comprehensive analysis of intratumor microbiome in head and neck squamous cell carcinoma</article-title>. <source>Eur. Arch. Otorhinolaryngol.</source> <volume>279</volume> (<issue>8</issue>), <fpage>4127</fpage>&#x2013;<lpage>4136</lpage>. <pub-id pub-id-type="doi">10.1007/s00405-022-07284-z</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warnakulasuriya</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Oral cancer screening: Past, present, and future</article-title>. <source>J. Dent. Res.</source> <volume>100</volume> (<issue>12</issue>), <fpage>1313</fpage>&#x2013;<lpage>1320</lpage>. <pub-id pub-id-type="doi">10.1177/00220345211014795</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>C. W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Turning up a new pattern: Identification of cancer-associated fibroblast-related clusters in TNBC</article-title>. <source>Front. Immunol.</source> <volume>13</volume>, <fpage>1022147</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2022.1022147</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Oral microbiota community dynamics associated with oral squamous cell carcinoma staging</article-title>. <source>Front. Microbiol.</source> <volume>9</volume>, <fpage>862</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.00862</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Oral microbiota analysis of tissue pairs and saliva samples from patients with oral squamous cell carcinoma - a pilot study</article-title>. <source>Front. Microbiol.</source> <volume>12</volume>, <fpage>719601</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2021.719601</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>V. B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The role of the microbiome in human health and disease: An introduction for clinicians</article-title>. <source>BMJ</source> <volume>356</volume>, <fpage>j831</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.j831</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C. P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The oral microbiota may have influence on oral cancer</article-title>. <source>Front. Cell Infect. Microbiol.</source> <volume>9</volume>, <fpage>476</fpage>. <pub-id pub-id-type="doi">10.3389/fcimb.2019.00476</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery</article-title>. <source>Int. J. Surg.</source> <volume>107</volume>, <fpage>106936</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106936</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>